CAR-T therapy utilizing Oncostatin-M ligand demonstrates significant anti-tumor efficacy in osteosarcoma treatment - Summary - MDSpire

CAR-T therapy utilizing Oncostatin-M ligand demonstrates significant anti-tumor efficacy in osteosarcoma treatment

  • By

  • Daniel Feinberg

  • Vinayak Uppin

  • Saada Eid

  • Claire Fritz

  • Masahiro Hitomi

  • Akshaya Radhakrishnan

  • Kayla Klatt

  • Sung Hee Choi

  • Jay T Myers

  • Aarshvi Bhatt

  • Duncan Stearns

  • Irina Pateva

  • Zachary D C Burke

  • Alex Y Huang

  • Gary K Schwartz

  • Reshmi Parameswaran

  • March 17, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy of CAR-T cells targeting Oncostatin-M receptors in treating osteosarcoma, highlighting the potential for improved patient outcomes.

Key Findings:
  • High expression of OSMR and LIFR on osteosarcoma cells suggests potential for targeted therapy, with implications for patient stratification.
  • OSM-CAR-T cells effectively killed osteosarcoma cells and released IFNγ, demonstrating a significant cytotoxic response.
  • Therapeutic efficacy was not observed in cells lacking OSMR/LIFR or in mice without cancer, indicating the specificity of the treatment.
Interpretation:

The findings indicate that OSM-CAR-T cells could be a promising therapeutic option for osteosarcoma, potentially improving outcomes for patients and warranting further clinical investigation.

Limitations:
  • The study primarily focuses on pre-clinical models, and clinical efficacy in humans remains to be established, posing a challenge for future application.
  • Further research is needed to assess the long-term effects and safety of OSM-CAR-T therapy, particularly in diverse patient populations.
Conclusion:

OSM-CAR-T therapy shows significant anti-tumor efficacy in osteosarcoma, highlighting the potential for CAR-T strategies targeting solid tumors and paving the way for future clinical trials.

Original Source(s)

CAR-T therapy utilizing Oncostatin-M ligand demonstrates significant anti-tumor efficacy in osteosarcoma treatment

  • by Daniel Feinberg, Vinayak Uppin, Saada Eid, Claire Fritz, Masahiro Hitomi, Akshaya Radhakrishnan, Kayla Klatt, Sung Hee Choi, Jay T Myers, Aarshvi Bhatt, Duncan Stearns, Irina Pateva, Zachary D C Burke, Alex Y Huang, Gary K Schwartz, Reshmi Parameswaran

  • March 17, 2026

Related Content

Case Report: Clinical case of a giant plexiform neurofibroma of the liver in a patient with deletion of exon 1 of the NF1 gene

ZNF25 as an immunotherapy target: pan-cancer biomarker potential and mechanistic exploration in glioma

Mechanisms and biomarkers of immune checkpoint inhibitor-associated myocarditis: from T cell imbalance to multicellular crosstalk